Peptide library › Cancer & imaging
LTX-315
Also known as Ruxotemitide
Experimental cancer-killing peptide injected directly into tumours to trigger an immune response.
What people use it for
- Solid tumours such as melanoma and sarcoma (in trials)
What LTX-315 does in the body
An oncolytic peptide that punches holes in cancer cell membranes. The dying cells release signals that help the immune system recognise the cancer, including tumours elsewhere in the body.
Strength of evidence
Moderate: early-phase trials showed injected tumours shrinking and immune activation.
Look up the evidence
- Reviews on PubMed: Summaries of the published research
- Clinical trials on PubMed: Published studies in people
- ClinicalTrials.gov: Registered trials, past and ongoing
Live searches of official databases. New to the terms? See the glossary.
Reported side effects & risks
- Pain at the injection site
- Low blood pressure and flushing
- Allergic reactions
Who should avoid it or take extra care
- Not available outside research
Not a complete list. Check with a doctor or pharmacist about your own health and medicines.
Regulatory status
Investigational. Not approved by the FDA.
How it's taken
Route: Injection directly into tumours (in trials)
How long it lasts (half-life): Not relevant: acts locally in the tumour
Keep track of LTX-315 privately
Fiala is a free app for logging doses, tracking vials and setting reminders. No account, and everything you log stays on your phone.
Open LTX-315 in Fiala How to installMore in Cancer & imaging
- DegarelixMonthly hormone-blocking injection for advanced prostate cancer that lowers testosterone fast, without an initial flare.
- Lutetium Lu-177 dotatateTargeted radiation therapy that delivers radiation straight to neuroendocrine tumours.
- Lutetium Lu-177 vipivotide tetraxetanTargeted radiation therapy for advanced prostate cancer that carries the PSMA protein.
- Gallium Ga-68 dotatateRadioactive tracer used in PET scans to find neuroendocrine tumours.
- MotixafortideInjection that releases stem cells from the bone marrow so they can be collected before a transplant for multiple myeloma.
- BalixafortideExperimental CXCR4 blocker studied with chemotherapy for advanced breast cancer; its Phase 3 trial failed.